Artículos de revistas
Jak2 V617f Mutation And The Myeloproliferative Disorders [a Mutação Jak2 V617f E As Síndromes Mieloproliferativas]
Registro en:
Revista Brasileira De Hematologia E Hemoterapia. , v. 30, n. 3, p. 241 - 248, 2008.
15168484
10.1590/S1516-84842008000300014
2-s2.0-54949104002
Autor
Monte-Mor B.C.R.
Costa F.F.
Institución
Resumen
Myeloproliferative disorders are clonal hematopoietic diseases that are characterized by the amplification of one or more myeloid lineages. Polycythemia vera, essential thrombocythemia, idiopathic myelofibrosis and chronic myeloid leukemia are considered classic myeloproliferative disorders and share common clinical and biological features. While the genetic basis of chronic myeloid leukemia is shown to be the constitutive active protein BCR-ABL, the main molecular lesions in polycythemia vera, essential thrombocythemia and idiopathic myelofibrosis remain unknown. This review focuses on the recent discovery of the JAK2 V617F mutation, its relationship to the myeloproliferative phenotype and implications in the clinical approach of patients. 30 3 241 248 Dameshek, W., Some speculations on the myeloproliferative syndromes (1951) Blood, 6 (4), pp. 372-375 Vardiman, J.W., Harris, N.L., Brunning, R.D., The World Health Organization (WHO) classification of the myeloid neoplasms (2002) Blood, 100 (7), pp. 2292-2302 Fialkow, P.J., Gartler, S.M., Yoshida, A., Clonal origin of chronic myelocytic leukemia in man (1967) Proc Natl Acad Sci USA, 58 (4), pp. 1468-1471 Adamson, J.W., Fialkow, P.J., Murphy, S., Prchal, J.F., Steinmann, L., Polycythemia vera: Stem-cell and probable clonal origin of the disease (1976) N Engl J Med, 295 (17), pp. 913-916 Jacobson, R.J., Salo, A., Fialkow, P.J., Agnogenic myeloid metaplasia: A clonal proliferation of hematopoietic stem cells with secondary myelofibrosis (1978) Blood, 51 (2), pp. 189-194 Fialkow, P.J., Faguet, G.B., Jacobson, R.J., Vaidya, K., Murphy, S., Evidence that essential thrombocythemia is a clonal disorder with origin in a multipotent stem cell (1981) Blood, 58 (5), pp. 916-919 Spivak, J.L., Barosi, G., Tognoni, G., Barbui, T., Finazzi, G., Marchioli, R., (2003) Chronic myeloproliferative disorders, pp. 200-224. , Hematology Am Soc Hematol Educ Program Prchal, J.F., Axelrad, A.A., Letter: Bone-marrow responses in polycythemia vera (1974) N Engl J Med, 290 (24), p. 1382 Dai, C.H., Krantz, S.B., Dessypris, E.N., Means Jr., R.T., Horn, S.T., Gilbert, H.S., Polycythemia vera. II. Hypersensitivity of bone marrow erythroid, granulocyte-macrophage, and megakaryocyte progenitor cells to interleukin-3 and granulocyte-macrophage colony-stimulating factor (1992) Blood, 80 (4), pp. 891-899 Correa, P.N., Eskinazi, D., Axelrad, A.A., Circulating erythroid progenitors in polycythemia vera are hypersensitive to insulin-like growth factor-1 in vitro: Studies in an improved serum-free medium (1994) Blood, 83 (1), pp. 99-112 Dai, C.H., Krantz, S.B., Green, W.F., Gilbert, H.S., Polycythaemia vera. III. Burst-forming units-erythroid (BFU-E) response to stem cell factor and c-kit receptor expression (1994) Br J Haematol, 86 (1), pp. 12-21 Axelrad, A.A., Eskinazi, D., Correa, P.N., Amato, D., Hypersensitivity of circulating progenitor cells to megakaryocyte growth and development factor (PEG-rHu MGDF) in essential thrombocythemia (2000) Blood, 96 (10), pp. 3310-3321 Deininger, M.W., Goldman, J.M., Melo, J.V., The molecular biology of chronic myeloid leukemia (2000) Blood, 96 (10), pp. 3343-3356 Cools, J., DeAngelo, D.J., Gotlib, J., Stover, E.H., Legare, R.D., Cortes, J., A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome (2003) N Engl J Med, 348 (13), pp. 1201-1214 Guasch, G., Delaval, B., Arnoulet, C., Xie, M.J., Xerri, L., Sainty, D., FOP-FGFR1 tyrosine kinase, the product of a t(6;8) translocation, induces a fatal myeloproliferative disease in mice (2004) Blood, 103 (1), pp. 309-312 Griesinger, F., Hennig, H., Hillmer, F., Podleschny, M., Steffens, R., Pies, A., A BCR-JAK2 fusion gene as the result of a t(9;22) (p24;q11.2) translocation in a patient with a clinically typical chronic myeloid leukemia (2005) Genes Chromosomes Cancer, 44 (3), pp. 329-333 Golub, T.R., Barker, G.F., Lovett, M., Gilliland, D.G., Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation (1994) Cell, 77 (2), pp. 307-316 Tefferi, A., Pardanani, A., Clinical, genetic, and therapeutic insights into systemic mast cell disease (2004) Curr Opin Hematol, 11 (1), pp. 58-64 Baxter, E.J., Scott, L.M., Campbell, P.J., East, C., Fourouclas, N., Swanton, S., Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders (2005) Lancet, 365 (9464), pp. 1054-1061 James, C., Ugo, V., Le Couedic, J.P., Staerk, J., Delhommeau, F., Lacout, C., A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera (2005) Nature, 434 (7037), pp. 1144-1148 Kralovics, R., Passamonti, F., Buser, A.S., Teo, S.S., Tiedt, R., Passweg, J.R., A gain-of-function mutation of JAK2 in myeloproliferative disorders (2005) N Engl J Med, 352 (17), pp. 1779-1790 Levine, R.L., Wadleigh, M., Cools, J., Ebert, B.L., Wernig, G., Huntly, B.J., Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis (2005) Cancer Cell, 7 (4), pp. 387-397 Zhao, R., Xing, S., Li, Z., Fu, X., Li, Q., Krantz, S.B., Identification of an acquired JAK2 mutation in polycythemia vera (2005) J Biol Chem, 280 (24), pp. 22788-22792 Ihle, J.N., Witthuhn, B.A., Quelle, F.W., Yamamoto, K., Silvennoinen, O., Signaling through the hematopoietic cytokine receptors (1995) Annu Rev Immunol, 13, pp. 369-398 Campbell, P.J., Green, A.R., The myeloproliferative disorders (2006) N Engl J Med, 355 (23), pp. 2452-2466 Monte-Mór, B.C.R., Cunha, A.F., Pagnano, K.B.B., Saad, S.T., Lorand-Metze, I., Costa, F.F., JAK2 V617F prevalence in Brazilian patients with polycythemia vera, idiopathic myelofibrosis and essential thrombocythemia (2007) Genet Mol Biol, 30 (2), pp. 336-338 Jones, A.V., Kreil, S., Zoi, K., Waghorn, K., Curtis, C., Zhang, L., Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders (2005) Blood, 106 (6), pp. 2162-2168 Jelinek, J., Oki, Y., Gharibyan, V., Bueso-Ramos, C., Prchal, J.T., Verstovsek, S., JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia (2005) Blood, 106 (10), pp. 3370-3373 Tefferi, A., Pardanani, A., Mutation screening for JAK2V617F: When to order the test and how to interpret the results (2006) Leuk Res, 30 (6), pp. 739-744 Levine, R.L., Loriaux, M., Huntly, B.J., Loh, M.L., Beran, M., Stoffregen, E., The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia (2005) Blood, 106 (10), pp. 3377-3379 Scott, L.M., Campbell, P.J., Baxter, E.J., Todd, T., Stephens, P., Edkins, S., The V617F JAK2 mutation is uncommon in cancers and in myeloid malignancies other than the classic myeloproliferative disorders (2005) Blood, 106 (8), pp. 2920-2921 Lee, J.W., Kim, Y.G., Soung, Y.H., Han, K.J., Kim, S.Y., Rhim, H.S., The JAK2 V617F mutation in de novo acute myelogenous leukemias (2006) Oncogene, 25 (9), pp. 1434-1436 Parganas, E., Wang, D., Stravopodis, D., Topham, D.J., Marine, J.C., Teglund, S., Jak2 is essential for signaling through a variety of cytokine receptors (1998) Cell, 93 (3), pp. 385-395 Roder, S., Steimle, C., Meinhardt, G., Pahl, H.L., STAT3 is constitutively active in some patients with Polycythemia rubra vera (2001) Exp Hematol, 29 (6), pp. 694-702 Silva, M., Richard, C., Benito, A., Sanz, C., Olalla, I., Fernandez-Luna, J.L., Expression of Bcl-x in erythroid precursors from patients with polycythemia vera (1998) N Engl J Med, 338 (9), pp. 564-571 Dai, C., Chung, I.J., Krantz, S.B., Increased erythropoiesis in polycythemia vera is associated with increased erythroid progenitor proliferation and increased phosphorylation of Akt/PKB (2005) Exp Hematol, 33 (2), pp. 152-158 Ugo, V., Marzac, C., Teyssandier, I., Larbret, F., Lecluse, Y., Debili, N., Multiple signaling pathways are involved in erythropoietin-independent differentiation of erythroid progenitors in polycythemia vera (2004) Exp Hematol, 32 (2), pp. 179-187 Kralovics, R., Guan, Y., Prchal, J.T., Acquired uniparental disomy of chromosome 9p is a frequent stem cell defect in polycythemia vera (2002) Exp Hematol, 30 (3), pp. 229-236 Kaushansky, K., On the molecular origins of the chronic myeloproliferative disorders: It all makes sense (2005) Blood, 105 (11), pp. 4187-4190 Delhommeau, F., Pisani, D.F., James, C., Casadevall, N., Constantinescu, S., Vainchenker, W., Oncogenic mechanisms in myeloproliferative disorders (2006) Cell Mol Life Sci, 63 (24), pp. 2939-2953 Villeval, J.L., James, C., Pisani, D.F., Casadevall, N., Vainchenker, W., New insights into the pathogenesis of JAK2 V617F-positive myeloproliferative disorders and consequences for the management of patients (2006) Semin Thromb Hemost, 32 (4 PART 2), pp. 341-351 Spivak, J.L., The chronic myeloproliferative disorders: Clonality and clinical heterogeneity (2004) Semin Hematol, 41 (2 SUPPL. 3), pp. 1-5 Pahl, H.L., Towards a molecular understanding of polycythemia rubra vera (2000) Eur J Biochem, 267 (12), pp. 3395-3401 Delhommeau, F., Dupont, S., Tonetti, C., Masse, A., Godin, I., Le Couedic, J.P., Evidence that the JAK2 G1849T (V617F) mutation occurs in a lymphomyeloid progenitor in polycythemia vera and idiopathic myelofibrosis (2007) Blood, 109 (1), pp. 71-77 Jamieson, C.H., Gotlib, J., Durocher, J.A., Chao, M.P., Mariappan, M.R., Lay, M., The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation (2006) Proc Natl Acad Sci USA, 103 (16), pp. 6224-6229 Lacout, C., Pisani, D.F., Tulliez, M., Gachelin, F.M., Vainchenker, W., Villeval, J.L., JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis (2006) Blood, 108 (5), pp. 1652-1660 Wernig, G., Mercher, T., Okabe, R., Levine, R.L., Lee, B.H., Gilliland, D.G., Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model (2006) Blood, 107 (11), pp. 4274-4281 Scott, L.M., Scott, M.A., Campbell, P.J., Green, A.R., Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia (2006) Blood, 108 (7), pp. 2435-2437 Passamonti, F., Rumi, E., Pietra, D., Della Porta, M.G., Boveri, E., Pascutto, C., Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders (2006) Blood, 107 (9), pp. 3676-3682 Campbell PJ, Scott LM, Buck G, Wheatley K, East CL, Marsden JT et al. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet. 2005 3 366 (9501):1945-53Tefferi, A., Lasho, T.L., Schwager, S.M., Strand, J.S., Elliott, M., Mesa, R., The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera (2006) Cancer, 106 (3), pp. 631-635 Andrieux, J.L., Demory, J.L., Karyotype and molecular cytogenetic studies in polycythemia vera (2005) Curr Hematol Rep, 4 (3), pp. 224-229 Xu, M.J., Sui, X., Zhao, R., Dai, C., Krantz, S.B., Zhao, Z.J., PTP-MEG2 is activated in polycythemia vera erythroid progenitor cells and is required for growth and expansion of erythroid cells (2003) Blood, 102 (13), pp. 4354-4360 Hookham, M.B., Elliott, J., Suessmuth, Y., Staerk, J., Ward, A.C., Vainchenker, W., The myeloproliferative disorder-associated JAK2 V617F mutant escapes negative regulation by suppressor of cytokine signaling 3 (2007) Blood, 109 (11), pp. 4924-4929 Moliterno, A.R., Williams, D.M., Gutierrez-Alamillo, L.I., Salvatori, R., Ingersoll, R.G., Spivak, J.L., Mpl Baltimore: A thrombopoietin receptor polymorphism associated with thrombocytosis (2004) Proc Natl Acad Sci USA, 101 (31), pp. 11444-11447 Bench, A.J., Pahl, H.L., Chromosomal abnormalities and molecular markers in myeloproliferative disorders (2005) Semin Hematol, 42 (4), pp. 196-205 Bellanne-Chantelot, C., Chaumarel, I., Labopin, M., Bellanger, F., Barbu, V., De Toma, C., Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disorders (2006) Blood, 108 (1), pp. 346-352 Campbell, P.J., Baxter, E.J., Beer, P.A., Scott, L.M., Bench, A.J., Huntly, B.J., Mutation of JAK2 in the myeloproliferative disorders: Timing, clonality studies, cytogenetic associations, and role in leukemic transformation (2006) Blood, 108 (10), pp. 3548-3555 Theocharides, A., Boissinot, M., Girodon, F., Garand, R., Teo, S.S., Lippert, E., Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation (2007) Blood, 110 (1), pp. 375-379 Staerk, J., Kallin, A., Royer, Y., Diaconu, C.C., Dusa, A., Demoulin, J.B., JAK2, the JAK2 V617F mutant and cytokine receptors (2007) Pathol Biol, 55 (2), pp. 88-91 Staerk, J., Kallin, A., Demoulin, J.B., Vainchenker, W., Constantinescu, S.N., JAK1 and Tyk2 activation by the homologous polycythemia vera JAK2 V617F mutation: Cross-talk with IGF1 receptor (2005) J Biol Chem, 280 (51), pp. 41893-41899 Huang, L.J., Constantinescu, S.N., Lodish, H.F., The N-terminal domain of Janus kinase 2 is required for Golgi processing and cell surface expression of erythropoietin receptor (2001) Mol Cell, 8 (6), pp. 1327-1338 Royer, Y., Staerk, J., Costuleanu, M., Courtoy, P.J., Constantinescu, S.N., Janus kinases affect thrombopoietin receptor cell surface localization and stability (2005) J Biol Chem, 280 (29), pp. 27251-27261 Moliterno, A.R., Hankins, W.D., Spivak, J.L., Impaired expression of the thrombopoietin receptor by platelets from patients with polycythemia vera (1998) N Engl J Med, 338 (9), pp. 572-580 Moliterno, A.R., Spivak, J.L., Posttranslational processing of the thrombopoietin receptor is impaired in polycythemia vera (1999) Blood, 94 (8), pp. 2555-2561 Lu, X., Levine, R., Tong, W., Wernig, G., Pikman, Y., Zarnegar, S., Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation (2005) Proc Natl Acad Sci USA, 102 (52), pp. 18962-18967 Pikman, Y., Lee, B.H., Mercher, T., McDowell, E., Ebert, B.L., Gozo, M., MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia (2006) PLoS Med, 3 (7), pp. e270 Pardanani, A.D., Levine, R.L., Lasho, T., Pikman, Y., Mesa, R.A., Wadleigh, M., MPL515 mutations in myeloproliferative and other myeloid disorders: A study of 1182 patients (2006) Blood, 108 (10), pp. 3472-3476 Scott, L.M., Tong, W., Levine, R.L., Scott, M.A., Beer, P.A., Stratton, M.R., JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis (2007) N Engl J Med, 356 (5), pp. 459-468 James, C., Delhommeau, F., Marzac, C., Teyssandier, I., Couedic, J.P., Giraudier, S., Detection of JAK2 V617F as a first intention diagnostic test for erythrocytosis (2006) Leukemia, 20 (2), pp. 350-353 McClure, R., Mai, M., Lasho, T., Validation of two clinically useful assays for evaluation of JAK2 V617F mutation in chronic myeloproliferative disorders (2006) Leukemia, 20 (1), pp. 168-171 Campbell, P.J., Scott, L.M., Baxter, E.J., Bench, A.J., Green, A.R., Erber, W.N., Methods for the detection of the JAK2 V617F mutation in human myeloproliferative disorders (2006) Methods Mol Med, 125, pp. 253-264 Tefferi, A., Thiele, J., Orazi, A., Kvasnicka, H.M., Barbui, T., Hanson, C.A., Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: Recommendations from an ad hoc international expert panel (2007) Blood, 110 (4), pp. 1092-1097 Goerttler, P.S., Steimle, C., Marz, E., Johansson, P.L., Andreasson, B., Griesshammer, M., The Jak2V617F mutation, PRV-1 overexpression, and EEC formation define a similar cohort of MPD patients (2005) Blood, 106 (8), pp. 2862-2864 Tefferi, A., Sirhan, S., Lasho, T.L., Schwager, S.M., Li, C.Y., Dingli, D., Concomitant neutrophil JAK2 mutation screening and PRV-1 expression analysis in myeloproliferative disorders and secondary polycythaemia (2005) Br J Haematol, 131 (2), pp. 166-171 Klippel, S., Strunck, E., Busse, C.E., Behringer, D., Pahl, H.L., Biochemical characterization of PRV-1, a novel hematopoietic cell surface receptor, which is overexpressed in polycythemia rubra vera (2002) Blood, 100 (7), pp. 2441-2448 Arellano-Rodrigo, E., Alvarez-Larran, A., Reverter, J.C., Villamor, N., Colomer, D., Cervantes, F., Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status (2006) Haematologica, 91 (2), pp. 169-175 Wolanskyj, A.P., Lasho, T.L., Schwager, S.M., McClure, R.F., Wadleigh, M., Lee, S.J., JAK2 mutation in essential thrombocythaemia: Clinical associations and long-term prognostic relevance (2005) Br J Haematol, 131 (2), pp. 208-213 Finazzi, G., Rambaldi, A., Guerini, V., Carobbo, A., Barbui, T., Risk of thrombosis in patients with essential thrombocythemia and polycythemia vera according to JAK2 V617F mutation status (2007) Haematologica, 92 (1), pp. 135-136 Vannucchi, A.M., Antonioli, E., Guglielmelli, P., Rambaldi, A., Barosi, G., Marchioli, R., Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia (2007) Blood, 110 (3), pp. 840-846 Campbell, P.J., Griesshammer, M., Dohner, K., Dohner, H., Kusec, R., Hasselbalch, H.C., V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis (2006) Blood, 107 (5), pp. 2098-2100 Kiladjian, J.J., Cassinat, B., Turlure, P., Cambier, N., Roussel, M., Bellucci, S., High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a (2006) Blood, 108 (6), pp. 2037-2040 Ruiz-Arguelles, G.J., Garces-Eisele, J., Reyes-Nunez, V., Ruiz-Delgado, G.J., Rosillo, C., Camoriano, J.K., Clearance of the Janus kinase 2 (JAK2) V617F mutation after allogeneic stem cell transplantation in a patient with myelofibrosis with myeloid metaplasia (2007) Am J Hematol, 82 (5), pp. 400-402 Mauro, M.J., O'Dwyer, M.E., Druker, B.J., ST1571, a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia: Validating the promise of molecularly targeted therapy (2001) Cancer Chemother Pharmacol, 48 (SUPPL. 1), pp. S77-S78